Epipole raises £1.5m in seed funding led by Greenwood Way Capital and the Scottish Investment Bank
The funding will prepare the company for its introduction into the United States ophthalmic imaging market.
Epipole designs and manufactures portable video retinal imaging technology intended to identify symptoms of preventable blindness. The ISO13485 certified medical device business produces handheld video ophthalmoscopes for clinicians.
Scottish retinal imaging specialist Epipole has secured £1.5m in a seed funding round to prepare for its entry into the United States market. The investment was led by Greenwood Way Capital alongside participation from the Scottish Investment Bank.
The company intends to direct the capital toward refining its handheld video ophthalmoscope based on feedback from ophthalmologists. The firm focuses on primary care optometry and ophthalmology in the United States, targeting product availability by early 2021.
Alongside the funding, Epipole announced the appointment of former Optos executive Ian Stevens as chairman. Stevens brings prior leadership experience from Scottish technology firms including Touch Bionics and Mpathy Medical.
From the founder
"We’ve worked with ophthalmologists to test and refine features and capabilities, and will use this funding to implement the key changes needed,"
Craig Robertson
CEO at Epipole
Use of funds
- 01Continue product development
